NATALIZUMAB FOR RAPIDLY EVOLVING SEVERE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RESRMS) PATIENTS: 5-YEAR BUDGET IMPACT ANALYSIS (BIA) FROM THE BRAZILIAN PUBLIC PAYER PERSPECTIVE

被引：0
|
作者：
Nishikawa, A. M. [1 ]
Paladini, L. [1 ]
Liamas, A. L. [2 ]
Bueno, C. C. [1 ]
Clark, O. A. C. [1 ]
机构：
[1] Evidencias, Campinas, SP, Brazil
[2] Biogen Idec Brasil, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1814
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A621 / A621
页数：1
相关论文
共 46 条
  • [1] NATALIZUMAB FOR 2ND LINE TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS: 5-YEAR BUDGET IMPACT ANALYSIS (BIA) FROM THE BRAZILIAN PUBLIC PAYER PERSPECTIVE
    Nishikawa, A. M.
    Paladini, L.
    Liamas, A. L.
    Bueno, C. C.
    Clark, O. A. C.
    VALUE IN HEALTH, 2013, 16 (07) : A720 - A720
  • [2] A network meta-analysis comparing alemtuzumab to natalizumab in patients with relapsing-remitting multiple sclerosis with rapidly evolving severe disease
    Guo, J. D.
    Das Gupta, R. J.
    Fahrbach, K.
    Wissinger, E.
    Cox, F. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 772 - 772
  • [3] COST-UTILITY ANALYSES OF NATALIZUMAB VERSUS INTERFERON BETA-1A 44 MCG FOR RAPIDLY EVOLVING SEVERE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RESRMS) PATIENTS IN BRAZIL
    Nishikawa, A. M.
    Paladini, L.
    Liamas, A. L.
    Bueno, C. C.
    Clark, O. A. C.
    VALUE IN HEALTH, 2013, 16 (07) : A624 - A624
  • [4] Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis
    Spelman, T.
    Acosta, C.
    Hyde, R.
    Campbell, N.
    Havrdova, E.
    Horakova, D.
    Trojano, M.
    De Luca, G.
    Lugaresi, A.
    Izquierdo, G.
    Grammond, P.
    Duquette, P.
    Alroughani, R.
    Pucci, E.
    Granella, F.
    Lechner-Scott, J.
    Sola, P.
    Ferraro, D.
    Grand-Maison, F.
    Terzi, M.
    Rozsa, C.
    Boz, C.
    Hupperts, R.
    Van der Walt, A.
    Van Pesch, V.
    Oreja-Guevara, C.
    Jokubaitis, V.
    Kalincik, T.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 526 - 527
  • [5] SOUVENAID® FOR THE DIETARY MANAGEMENT OF MILD ALZHEIMER'S DISEASE: 5-YEAR BUDGET IMPACT ANALYSIS (BIA) FROM THE BRAZILIAN PUBLIC PAYER PERSPECTIVE (SUS)
    Borges, L.
    Feijo, L. F.
    Clark, O. A. C.
    Souza, T. T.
    Sturion, C.
    Gumbs, P.
    Wallace, M.
    VALUE IN HEALTH, 2014, 17 (03) : A58 - A59
  • [6] COST-UTILITY ANALYSIS OF ALEMTUZUMAB VERSUS NATALIZUMAB FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: US PAYER PERSPECTIVE
    Smith, A.
    Hashemi, L.
    Ma, I
    VALUE IN HEALTH, 2016, 19 (07) : A431 - A431
  • [7] Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
    Spelman, T.
    Herring, W. L.
    Acosta, C.
    Hyde, R.
    Jokubaitis, V. G.
    Pucci, E.
    Lugaresi, A.
    Laureys, G.
    Havrdova, E. K.
    Horakova, D.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Alroughani, R.
    Kalincik, T.
    Duquette, P.
    Girard, M.
    Petersen, T.
    Patti, F.
    Csepany, T.
    Granella, F.
    Grand'Maison, F.
    Ferraro, D.
    Karabudak, R.
    Jose Sa, M.
    Trojano, M.
    van Pesch, V.
    Van Wijmeersch, B.
    Cartechini, E.
    Mccombe, P.
    Gerlach, O.
    Spitaleri, D.
    Rozsa, C.
    Hodgkinson, S.
    Bergamaschi, R.
    Gouider, R.
    Soysal, A.
    Prevost, J.
    Garber, J.
    de Gans, K.
    Ampapa, R.
    Simo, M.
    Sanchez-Menoyo, J. L.
    Iuliano, G.
    Sas, A.
    van der Walt, A.
    John, N.
    Gray, O.
    Hughes, S.
    De Luca, G.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 109 - 125
  • [8] A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK
    Montgomery, Stephen M.
    Maruszczak, Maciej J.
    Slater, David
    Kusel, Jeanette
    Nicholas, Richard
    Adlard, Nicholas
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (05) : 474 - 482
  • [9] BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S205 - S205
  • [10] Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
    Huisman, Eline
    Papadimitropoulou, Katerina
    Jarrett, James
    Bending, Matthew
    Firth, Zoe
    Allen, Felicity
    Adlard, Nick
    BMJ OPEN, 2017, 7 (03):
12345